Skip to main
OPNV
Privately held company

OpenEvidence

$504.80

Source: Nasdaq Private Markets
$285.99 (130.70%)past six months

OpenEvidence Valuation

Follow estimated valuations, share price trends, and company updates for OpenEvidence.

Get updates

About OpenEvidence

OpenEvidence delivers an AI-driven platform that helps healthcare professionals effortlessly explore and understand medical research. It synthesizes peer-reviewed clinical studies and multimedia into digestible insights that support informed decision making at the point of care. The platform seamlessly integrates evidence-based content into clinicians’ workflows to enhance patient outcomes.
Co-FounderZachary Ziegler
CEODaniel Nadler
CTOZachary Ziegler
HeadquartersCambridge, MA
Founded2019
SectorHealthcare & Life Sciences

OpenEvidence Funding History

Financing RoundDateAmount
Series DJan 21, 2026$225M
Series C-2Oct 20, 2025$125M
Series C-2Oct 20, 2025$75M
Series B-1Jul 15, 2025$125M
Series B-1Jul 15, 2025$30M
Series AFeb 19, 2025$75M

OpenEvidence lead investors

  • Blackstone
  • BOND
  • Coatue
  • Craft Ventures
  • DST Global
  • Google Ventures
  • Greycroft
  • Kleiner Perkins Caufield & Byers
  • Sequoia
  • Thrive Capital

FAQ

Frequently asked questions

OpenEvidence's estimated secondary market share price is $504.80 as of May 2026.

OpenEvidence's last official round, Series D, was for $225M.

OpenEvidence's last known funding was on Jan 21, 2026 for $225M.

OpenEvidence's major investors are Blackstone, BOND, Coatue, Craft Ventures, DST Global, Google Ventures, Greycroft, Kleiner Perkins Caufield & Byers, Sequoia, Thrive Capital.

As of June 11, 2026, OpenEvidence is not yet publicly traded.

OpenEvidence Valuation

Follow estimated valuations, share price trends, and company updates for OpenEvidence.

Get updates